Paciente do sexo feminino, 37 anos, portadora de estenose mitral de etiologia reumática, submetida, com sucesso, a valvotomia mitral percutânea em 1996, 2000 e 2005. Após 41 meses do terceiro procedimento, além de episódios de fibrilação atrial paroxística, voltou a apresentar dispneia aos moderados esforços. O estudo ecocardiográfico demonstrou gradiente transvalvar médio de 8 mmHg, pressão sistólica da artéria pulmonar de 55 mmHg, área valvar mitral de 1 cm² e escore de Wilkins de 10 pontos. Em decorrência da evidência de reestenose clínica e ecocardiográfica, indicou-se novo procedimento percutâneo, realizado sem intercorrências, porém obtendo-se resultado subótimo.

Thirty-seven-year-old female, previously diagnosed with mitral valve stenosis due to rheumatic fever, who had successfully undergone percutaneous mitral valvotomy in 1996, 2000 and 2005. Forty-one months after the third procedure, in addition to episodes of paroxystic atrial fibrillation, the patient had dyspnea after ordinary exertion. Echocardiographic evaluation revealed a mean transvalvular gradient of 8 mmHg, pulmonary artery systolic pressure of 55 mmHg, a mitral valve area of 1 cm², and a Wilkins score of 10 points. With the evidence of clinical and echo-cardiographic mitral restenosis, a new percutaneous procedure was performed, with no periprocedural complications, however, achieving suboptimal outcome.

INTRODUÇÃO: As causas de reestenose pós-valvotomia mitral percutânea dependem principalmente das características da população submetida à técnica. O objetivo deste trabalho foi comparar os resultados imediatos e tardios dos pacientes submetidos a dois ou mais procedimentos de valvotomia mitral percutânea (VMP) a um grupo de pacientes submetidos apenas a uma dilatação para o tratamento da estenose mitral grave. MÉTODO: Os pacientes foram divididos em dois grupos: o grupo A incluiu 90 pacientes submetidos a uma primeira VMP e que, em decorrência de reestenose ecocardiográfica e clínica, foram encaminhados a uma segunda intervenção, e 9 pacientes que, pelo mesmo motivo, foram submetidos a um terceiro procedimento; e grupo B, composto de 90 pacientes selecionados por amostra aleatória simples submetidos a apenas uma dilatação, todas com sucesso. As variáveis ecocardiográficas analisadas para comparação dos resultados dentro do mesmo grupo e entre os grupos A e B foram a área valvar mitral (AVM), os gradientes diastólicos máximo (GDM) e médio (GDm), o diâmetro do átrio esquerdo e a incidência de reestenose. RESULTADOS: Nos pacientes do grupo A, a primeira dilatação foi realizada com sucesso em 87 (96,7%) pacientes. Comparativamente, a média das áreas valvares após a primeira dilatação dos pacientes que compõem o grupo A foi menor que a dos pacientes do grupo B (1,97 ± 0,17 cm² vs. 2,10 ± 0,33 cm²; P = 0,011). Em ambos os grupos, não se observou diferença estatisticamente significante, pré e imediatamente após o primeiro procedimento, na redução da média do GDM e do GDm e na média dos diâmetros do átrio esquerdo. Nos pacientes do grupo A, após a segunda valvotomia, os critérios de sucesso foram alcançados em 77 (85,5%) pacientes. A média das áreas valvares, nessa oportunidade, foi menor que após a primeira intervenção (1,83 ± 0,28 cm² vs. 1,97 ± 0,17 cm²; P < 0,005). Ainda dentro desse mesmo grupo, observou-se queda significativa do GDM e do GDm quando comparados os valores após o primeiro e o segundo procedimentos. Uma terceira dilatação foi realizada com 100% de sucesso nos 9 pacientes do grupo A. Resultados semelhantes aos anteriores foram obtidos na comparação das mesmas variáveis após a segunda e a terceira dilatações. O tempo médio para o aparecimento da reestenose ecocardiográfica entre a primeira, a segunda e a terceira dilatações foi de 54,12 meses, 25,23 meses e 29,30 meses, respectivamente. CONCLUSÃO: A obtenção de áreas valvares e o tempo para o aparecimento da reestenose significativamente menores imediatamente após uma segunda ou terceira valvotomias mitrais percutâneas, quando comparadas à primeira, não devem ser fatores para contraindicação do procedimento. Apesar de menores, as AVMs obtidas após uma segunda ou terceira intervenção enquadram-se, na maioria dos casos, dentro dos parâmetros de sucesso do procedimento, justificando assim sua indicação em casos selecionados.

BACKGROUND: The causes for restenosis following percutaneous balloon mitral valvotomy (PBMV) vary according to the population undergoing this technique. The aim of this study was to compare the immediate and long-term results of patients undergoing a second and third PBMV to patients submitted to a single dilatation of the mitral valve for the treatment of severe mitral stenosis. METHODS: Patients were divided into two groups: group A with 90 patients who, due to clinical and echocardiographic restenosis, were submitted to more than one procedure, and group B with 90 patients, selected by a random sample who underwent a single successful procedure. The echocardiographic variables analyzed to compare the results in the same group and between groups A and B were mitral valve area (MVA), maximal and mean diastolic gradients, left atrial diameter and incidence and time to restenosis. RESULTS: In group A, the first dilatation was successfully performed in 87 (96.7%) patients. Mean MVA after the first dilatation was smaller in group A patients than in group B patients (1.97 ± 0.17 cm² vs. 2.10 ± 0.33 cm²; P = 0.011). In both groups there was no statistically significant difference before and immediately after the first procedure in the reduction of the maximal and mean diastolic gradients and in mean LA diameters. In group A patients, success criteria were achieved in 77 (85.5%) patients after the second procedure. Mean MVA at this time was smaller than after the first PBMV (1.83 ± 0.28 cm² vs. 1.97 ± 0.17 cm²; P < 0.005). A significant decrease was observed for the maximal and mean diastolic gradients after the first and the second dilatation in this group. A third PBMV was successfully performed in all nine patients in the same group. Improvement of echocardiographic parameters was also observed in patients submitted to a second and third PBMV. Mean time to echocardiographic restenosis between the first, second and third PBMV was 54.12, 25.23 and 29.30 months, respectively. CONCLUSIONS: Smaller MVA and earlier restenosis were observed after a second and third PBMV when compared to the first dilatation; however, these findings do not contraindicate the procedure. Although smaller, mitral valve areas achieved immediately after these procedures were still within the success range for the procedure in most of these patients and justify repeated PBMV in selected cases.

OBJETIVO: Verificar a sensibilidade e a especificidade do hormônio natriurético do tipo B (BNP) para identificar pacientes ambulatoriais, com insuficiência mitral crônica grave, sintomáticos e assintomáticos. MÉTODOS: Um grupo de pacientes com insuficiência mitral foi examinado e submetido à eletrocardiografia, telerradiografia de tórax, coletas de sangue venoso e ecocardiograma transtorácico. Por meio da análise de variáveis ecocardiográficas, 62 pacientes apresentavam refluxo mitral discreto e moderado (G I) e 34 refluxo mitral grave (G II). A capacidade discriminante do BNP em detectar pacientes com insuficiência mitral grave foi avaliada pela construção de curvas ROC. RESULTADOS: Entre os 96 doentes, 71 (73%) eram mulheres e as idades variaram entre 15 e 63 (média de 31,7) anos. Os valores de BNP variaram de 0,00 pg/ml a 193 pg/ml. Os doentes do G I tiveram um valor médio de BNP de 18,10 ± 0,74 pg/ml e os do G II de 50,54 ± 1,46 pg/ml, (p=0,001). O valor de corte para identificar insuficiência mitral grave foi de 15,40 pg/ml, para o melhor balanço entre a sensibilidade e a especificidade, respectivamente de 0,73 e 0,74. O valor de corte para identificar pacientes sintomáticos e com insuficiência mitral grave foi de 28,40 pg/ml, para o melhor balanço entre a sensibilidade e a especificidade, respectivamente de 0,78 e 0,83. CONCLUSÃO: Os valores de BNP capazes de indentificar doentes com insuficiência mitral grave assintomáticos e sintomáticos são menores do que os 100 pg/ml considerados para o diagnóstico de insuficiência cardíaca.

OBJECTIVE: To assess the sensitivity and specificity of B-type natriuretic peptide (BNP) for identifying symptomatic and asymptomatic patients with severe chronic mitral regurgitation followed up on an outpatient care basis. METHODS: A group of patients with mitral regurgitation underwent electrocardiography, chest teleradiography, venous blood withdrawal, and transthoracic echocardiography. Based on an analysis of the echocardiographic variables, 62 patients had mild and moderate mitral regurgitation (GI) and 34 had severe mitral regurgitation (GII). The discriminating capacity of the BNP for detecting patients with severe mitral regurgitation was assessed by use of ROC curves. RESULTS: The patients' ages ranged from 15 to 63 (mean, 31.7) years, and of the 96 patients, 71 (73%) were females. The BNP values ranged from 0.00 pg/mL to 193 pg/mL. The mean BNP values in GI and GII patients were 18.10 ± 0.74 pg/mL and 50.54 ± 1.46 pg/mL, respectively (P=0.001). The cutoff point for identifying severe mitral regurgitation was 15.40 pg/mL for the best balance between sensitivity and specificity, which were 0.73 and 0.74, respectively. The cutoff point for identifying symptomatic patients with severe mitral regurgitation was 28.40 pg/mL for the best balance between sensitivity and specificity, which were 0.78 and 0.83, respectively. CONCLUSION: The BNP values capable of identifying asymptomatic and symptomatic patients with severe mitral regurgitation are lower than 100 pg/mL, which is considered for the diagnosis of heart failure.

OBJECTIVE: To assess the short- and long-term results of the use of streptokinase (SK) for the treatment of thromboses in cardiac valvular prostheses. METHODS: Seventeen patients with cardiac prosthetic thrombosis diagnosed by clinical, echocardiographic, and radioscopic findings underwent fibrinolytic treatment with a streptokinase bolus of 250,000 U followed by 100.000 U/hour. Short- and long-term results were assessed by radioscopy and echocardiography. RESULTS: Of the 17 patients, 12 had mechanical double-disk prostheses (4 aortic, 6 mitral, 2 tricuspid), 4 had single-disk prostheses (2 aortic, 1 mitral, and 1 tricuspid), and 1 had a tricuspid bioprosthesis. The success rate was 64.8%, the partial success rate was 17.6%, and the nonsuccess rate was 17.6%. All patients with a double-disk prosthesis responded, completely or partially, to the treatment. None of the patients with a single-disk prosthesis had complete resolution of the thrombosis. The time of streptokinase infusion ranged from 6 to 80 hours (mean of 56 h). The mortality rate due to the use of streptokinase was 5.8% and was secondary to cerebral bleeding. During streptokinase infusion, 3 (17.6%) embolic episodes occurred as follows: 1 cerebral, 1 peripheral, and 1 coronary. The rethrombosis index was 33% in a mean follow-up of 42 months. CONCLUSION: The use of fibrinolytic agents was effective and relatively safe in patients with primary thrombosis of a double-disk prosthesis. A fatal hemorrhagic complication occurred in 1 (5.8%) patient, and embolic complications occurred in 3 (17.6%) patients. In a mean 42-month follow-up, 67% of the patients were free from rethrombosis.

OBJECTIVE - To assess mortality and the psychological repercussions of the prolonged waiting time for candidates for heart surgery. METHODS - From July 1999 to May 2000, using a standardized questionnaire, we carried out standardized interviews and semi-structured psychological interviews with 484 patients with coronary heart disease, 121 patients with valvular heart diseases, and 100 patients with congenital heart diseases. RESULTS - The coefficients of mortality (deaths per 100 patients/year) were as follows: patients with coronary heart disease, 5.6; patients with valvular heart diseases, 12.8; and patients with congenital heart diseases, 3.1 (p<0.0001). The survival curve was lower in patients with valvular heart diseases than in patients with coronary heart disease and congenital heart diseases (p<0.001). The accumulated probability of not undergoing surgery was higher in patients with valvular heart diseases than in the other patients (p<0.001), and, among the patients with valvular heart diseases, this probability was higher in females than in males (p<0.01). Several patients experienced intense anxiety and attributed their adaptive problems in the scope of love, professional, and social lives, to not undergoing surgery. CONCLUSION - Mortality was high, and even higher among the patients with valvular heart diseases, with negative psychological and social repercussions.